

Pralsetinib ARROW

**PRELIMINARY SCORE**

**CURATIVE**



**NON-CURATIVE**



**ADJUSTMENTS**

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Pralsetinib ARROW

**FINAL SCORE**

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Endocrine Tumours

Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory

Experimental Arm: Pralsetinib

Control Arm: Single arm



